Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Atsuta, Yoshiko  [Clear All Filters]
2022
Tamaki M, Kameda K, Kimura S-I, Harada N, Uchida N, Doki N, Tanaka M, Ikegame K, Sawa M, Katayama Y, et al. Deletion of Y-chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood Adv. 2022.
Okada Y, Nakasone H, Konuma T, Uchida N, Tanaka M, Sugio Y, Aotsuka N, Nishijima A, Katsuoka Y, Ara T, et al. Ideal body weight is useful for predicting neutrophil engraftment and platelet recovery for overweight and obese recipients in single-unit cord blood transplantation. Transplant Cell Ther. 2022.
Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, et al. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Hematol Oncol. 2022.
Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, Nakamae H, Matsuoka K-I, Ara T, Washio K, et al. The Registry Data Analysis of HSCT on Systemic Chronic Active EBV Infection Patients in Japan. Am J Hematol. 2022.
Kimura S-I, Kameda K, Harada K, Saburi M, Okinaka K, Shinohara A, Uchida N, Nishijima A, Ozawa Y, Tanaka M, et al. Risk and predictive factors for candidemia after allogeneic hematopoietic cell transplantation: JSTCT Transplant Complications Working Group. Transplant Cell Ther. 2022.
2021
Shiratori S, Kurata M, Sugita J, Ota S, Kasahara S, Ishikawa J, Imada K, Onishi Y, Ishiyama K, Ashida T, et al. Graft-versus-host disease prophylaxis using low-dose antithymocyte globulin in peripheral blood stem cell transplantation - A matched-pair analysis. Transplant Cell Ther. 2021.
Sakurai M, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, et al. Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2021.
Inoue T, Koyama M, Kaida K, Ikegame K, Ensbey KS, Samson L, Takahashi S, Zhang P, Minnie SA, Maruyama S, et al. Peri-transplant glucocorticoids redistribute donor T-cells to the bone marrow and prevent relapse after haploidentical SCT. JCI Insight. 2021.
Konuma T, Aoki J, Ozawa Y, Uchida N, Kobayashi T, Onizuka M, Katayama Y, Ohta T, Nakano N, Ota S, et al. Pre-transplant red blood cell and platelet transfusion burden in de novo myelodysplastic syndrome undergoing allogeneic transplantation: Pre-transplant red blood cell and platelet transfusion burden in de novo MDS after allogeneic transplantation. Transplant Cell Ther. 2021.
Yamamoto S, Kato M, Watanabe K, Ishimaru S, Hasegawa D, Noguchi M, Hama A, Sato M, Koike T, Iwasaki F, et al. Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. Bone Marrow Transplant. 2021.
2020
Kawashima N, Ishikawa Y, Atsuta Y, Sawa M, Ozawa Y, Hayashi M, Kohno A, Tomita A, Maeda T, Sakaida E, et al. Allogeneic HSCT at the first remission for younger adults with FLT3-ITD AML: The JALSG AML209-FLT3-SCT Study. Cancer Sci. 2020.
Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, et al. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020.
Akahoshi Y, Kimura S-I, Inamoto Y, Seo S, Muranushi H, Shimizu H, Ozawa Y, Tanaka M, Uchida N, Kanda Y, et al. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2020.
Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, et al. Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplantation and its differences among disease risk or types. Biol Blood Marrow Transplant. 2020.
Takahashi T, Suzuki R, Yamamoto G, Nakazawa H, Kurosawa M, Kobayashi T, Okada M, Akasaka T, Kim S-W, Fukuda T, et al. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan. Hematol Oncol. 2020.
Kaito S, Nakajima Y, Hara K, Toya T, Nishida T, Uchida N, Mukae J, Fukuda T, Ozawa Y, Tanaka M, et al. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv. 2020;4(6):1051-1061.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, et al. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020.
Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Ogata M, Sugio Y, Fukuda T, Uchida N, Ikegame K, Matsuoka K-I, et al. Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab. Hematol Oncol. 2020.
Takenaka K, Onishi Y, Mori T, Hirakawa T, Tada Y, Uchida N, Kobayashi T, Kanda Y, Ozawa Y, Ota S, et al. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia After an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of . Biol Blood Marrow Transplant. 2020.
Kida M, Usuki K, Uchida N, Fukuda T, Katayama Y, Kondo T, Eto T, Matsuoka K-I, Matsuhashi Y, Ota S, et al. Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. Biol Blood Marrow Transplant. 2020.
Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka K-I, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation: Allo-HSCT for patient. Biol Blood Marrow Transplant. 2020.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, Shono K, Ota S, Fukuda T, Uchida N, et al. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W. Bone Marrow Transplant. 2020.
2019
Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, Uchida N, Fukuda T, Ichinohe T, Atsuta Y, et al. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantatio. Br J Haematol. 2019.

Pages